Nebenwirkungen · Vevzuo
Vevzuo 120 mg solution for injection · Abschnitt 4.8 · PDF-Seite 6
HOS-153298 · Präparat HOS-100962
Hypocalcaemia has very commonly been reported following denosumab administration, mostly within the first 2 weeks. Hypocalcaemia can be severe and symptomatic (see section 4.8 - description of selected adverse reactions). The decreases in serum calcium were generally appropriately managed by calcium and vitamin D supplementation. The most common adverse reactions with denosumab are musculoskeletal pain. Cases of osteonecrosis of the jaw (see sections 4.4 and section 4.8 - description of selected adverse reactions) have been commonly observed in patients taking denosumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-17T09:08:00Z · SHA-256 62447120a0dd72ad6043dd799725298b12ec6ff2c23546d2a5f4d3312480e3d3 · Passage f777e7b00d8145e9b850e5951ec6f20f6a6c667b7e934d59c28a0b90bc52ab2a · Zeichen 109–686 im Abschnitt